



18TH INTERNATIONAL SYMPOSIUM ON **THROMBOEMBOLISM**

14-15 OCTOBER 2011, THE QUEEN ELIZABETH II CONFERENCE CENTRE, LONDON, UK



Delegate Book

Front cover image: The London Eye and the Houses of Parliament, London.

Dear Colleagues,

Welcome to the annual International Symposium on Thromboembolism, organised under the auspices of the Thrombosis Research Institute, and now in its 18th year. The symposium continues to unite global thought leaders to share their expertise in the rapidly developing field of thromboembolism with you at this informative and rewarding meeting.

As you will see from the enclosed programme, highlights of the meeting include an exciting range of in-depth plenary sessions covering the challenges of venous thromboembolism, cancer-associated and arterial thrombosis, as well as interactive workshops, “meet the expert” sessions, and a debate. These popular sessions offer a unique opportunity to explore many topics ranging from special populations to acute coronary syndrome and thromboembolic stroke.

I hope that the excellent scientific programme and the outstanding historical surroundings here in Westminster will ensure that you enjoy your time with us in London.

With best wishes,



Lord Kakkar
Chair



Providing excellence in research, education, and patient care, and internationally renowned for pioneering, multidisciplinary research, the Thrombosis Research Institute comprises 2 independent charitable foundations based in London, United Kingdom, and Bangalore, India. The Thrombosis Research Institutes are dedicated to the study of thrombosis and related disorders.

The 2 research establishments are united by their shared mission: To provide excellence in thrombosis research, education, and patient care, and to develop new strategies to prevent and treat thrombosis, thereby reducing health care costs and saving millions of lives.

The Thrombosis Research Institute, London, was established in 1989, with the backing of then Prime Minister, Margaret Thatcher. It was created specifically to conduct research in cardiovascular disease (of the heart and blood vessels), a major cause of death and disability throughout the world.

This was followed in 2006 with the founding of the Thrombosis Research Institute in Bangalore, which was officially opened and dedicated to the nation by then president of India, His Excellency Dr APJ Abdul Kalam. This second facility was set up to study the genetics of heart disease, particularly among the South Asian population, many of whom seem to have specific predisposing genetic characteristics, and to develop novel and affordable therapies for disease prevention and treatment.

The 2 institutions, whose combined research activities encompass drug discovery and basic scientific, clinical, and epidemiological studies, are primarily concerned with understanding the disease process, developing novel and affordable therapies, and identifying those most at risk at an early age.

In addition, the London Institute is heavily involved in promoting the adoption of evidence-based methods of prevention and treatment to ensure that knowledge from groundbreaking research quickly informs routine clinical practice and benefits patients as soon as possible.

For more information, please visit the Thrombosis Research Institute's website at **www.tri-london.ac.uk**.

Programme Overview

The 18th International Symposium on Thromboembolism (IST), will focus on the advances and changes in the field of thromboembolism, while maintaining its commitment to the presentation of evidence-based medicine and helping clinicians translate research into clinical practice. The combination of the various formats at the IST allows attendees to be exposed to new data and allows for interactivity with colleagues from around the world.

Learning Objectives

- Evaluate current understanding of clinical evidence and key guidelines supporting cancer-associated thrombosis and venous and arterial thromboembolic disease
- Provide comprehensive overview of the state-of-the-art in the treatment of venous and arterial thromboembolic disease
- Compare results of clinical trials to guide considerations for patient care and outcomes
- Integrate advances demonstrated in clinical trials and guidelines into daily practice

Target Audience

Cardiologists, oncologists, surgeons, haematologists, general practitioners, internal medicine specialists, pharmacists, nurses, and other health care professionals involved in the care of patients at risk or with thromboembolic disease.

Accreditation

This activity has been planned and implemented by Thrombosis Education Ltd. in accordance with all requirements from the Royal College of Physicians (RCP) and the European Accreditation Council for Continuing Medical Education (EACCME).

This event has been accredited by the RCP for a maximum of 10 credits. The RCP activity code number is 68222.

This event has been accredited by the EACCME for a maximum of 8 European CME credits (ECMEC). The EACCME event code is 6489.

Educational Support

The event is supported by an unrestricted educational grant from Bristol-Myers Squibb, Pfizer and Bayer Healthcare Pharmaceuticals.


Level 4




Level 5



Level 6





Day One

Friday 14 October 2011

08.45-09.00	Welcome <i>Lord Kakkar, UK (Chair)</i>	<i>Mountbatten Room</i>
09.00-10.30	Plenary Session I: Cancer-Associated Thrombosis <i>Co-Chairs: C Kessler, USA and H Büller, The Netherlands</i> What is the appropriate duration of secondary prophylaxis? <i>Lord Kakkar, UK</i> Is there a role for primary VTE prophylaxis in the medical oncology patient? <i>C Kessler, USA</i> Do we really understand the burden of thrombosis in cancer? <i>M Levine, Canada</i>	<i>Mountbatten Room</i>
10.30-11.00	Coffee Break	<i>Mountbatten Lounge</i>
11.00-12.30	Plenary Session II: Venous Thrombosis <i>Co-Chairs: S Haas, Germany and VV Kakkar, UK</i> What is the role of parenteral therapy in VTE treatment? <i>H Büller, The Netherlands</i> Is there a balance of risk and benefit for prophylaxis in acutely ill medical patients? <i>J Eikelboom, Canada</i> Surgical patients and extended thromboprophylaxis: Is there a real need? <i>J Arcelus, Spain</i>	<i>Mountbatten Room</i>
12.30-13.00	Novel Oral Anticoagulant Update: Rivaroxaban <i>AGG Turpie, Canada</i>	
13.00-14.30	Lunch	<i>Mountbatten Lounge</i>
14.30-15.30/ 16.00-17.00	Workshops: Two 15 minute talks followed by 30 minute discussion. Delegates to attend 2 workshops and use coffee break to change rooms. 1. Special Populations a) Women's health <i>I Greer, UK</i> b) Recurrent thromboembolism <i>P Prandoni, Italy</i> 2. Cancer-Associated Thrombosis a) Can we predict thrombosis risk in the cancer patient? <i>C Kessler, USA</i> b) Should we treat incidental thrombi? <i>M Levine, Canada</i> 3. Acute Coronary Syndrome a) Drugs and devices to optimize reperfusion of ST-elevation myocardial infarction <i>G Montalescot, France</i> b) Adjunctive therapy after ACS: Too much or too little? <i>KAA Fox, UK</i> 4. Thromboembolic Stroke a) A continuing role for warfarin? <i>AGG Turpie, Canada</i> b) Can we improve patient outcomes through treating comorbidities? <i>JP Bassand, France</i>	<i>Henry Moore</i> <i>Wesley</i> <i>Rutherford</i> <i>Abbey</i>
15.30-16.00	Coffee Break	<i>Mountbatten Lounge</i>

Day Two

Saturday 15 October 2011

09.00-10.00

Meet the Expert Sessions

Breakout Rooms

Novel Antithrombotic Agents – A Personal View

Session A: *AGG Turpie, Canada*

Henry Moore

Session B: *H Büller, The Netherlands*

Rutherford

Session C: *H Bounameaux, Switzerland*

Abbey

Session D: *J Arcelus, Spain*

Wesley

10.00-10.30

Coffee

Mountbatten Lounge

10.30-12.00

Plenary Session III: Arterial Thrombosis

Mountbatten Room

Co-Chairs: JP Bassand, France and AGG Turpie, Canada

Better recognition of sub-clinical AF could substantially reduce population burden of ischemic stroke

S Connolly, Canada

Do anticoagulants have a role in secondary prevention of ACS?

F Verheugt, The Netherlands

Will novel antiplatelet agents make aspirin use unnecessary?

C Bode, Germany

12.00-12.45

Debate

Chair: Lord Kakkar, UK

Xa inhibition is a superior target to IIa for anticoagulant therapy

For: *C Granger, USA*

Against: *S Connolly, Canada*

12.45-13.15

Novel Oral Anticoagulant Update: Apixaban

C Granger, USA

13.15-13.30

Closing Remarks

13.30

Lunch



Sylvia Haas

Technical University of Munich, Munich, Germany

Sylvia Haas, MD, is currently an emeritus professor of medicine and former director of the Haemostasis and Thrombosis Research Group at the Institute for Experimental Oncology and Therapy Research, Technical University of Munich, a position she held for almost 30 years. Professor Haas received her medical degree from the University of Freiburg and began her training in paediatric haematology and oncology at the Department of Pediatrics, University of Munich. She continued her training in internal medicine at the Technical University of Munich and received full professorship after having established the Haemostasis and Thrombosis Research Group at the Institute for Experimental Surgery, now the Institute for Experimental Oncology and Therapy Research.



Professor Haas's scientific focus is on the development of new antithrombotic therapies, laboratory monitoring of anticoagulants, biomarkers, and tumour-associated thrombosis. She is involved in several clinical trials, in particular, trials in the prevention and treatment of arterial and venous thromboembolism. She is also in charge of various integrated teaching programmes.

Professor Haas is a member of several professional societies, including the International Society on Thrombosis and Haemostasis, the International Society of Angiology, the European Society for Surgical Research, and the German Societies of Surgery, Angiology, and Thrombosis and Haemostasis Research. She is a fellow of the Southern African Society of Thrombosis and Haemostasis and is a member of several editorial boards for peer-reviewed journals, including *International Angiology* and *Clinical and Applied Thrombosis/Hemostasis*.



Lord Kakkar

University College London Hospitals NHS Foundation Trust, University College London Partners Academic Health Sciences System and Thrombosis Research Institute, all in London, United Kingdom

Professor the Lord Kakkar, MBBS, BSc, PhD, FRCS, is professor of surgery, University College London; a consultant surgeon at the University College Hospital; chair of the Clinical Quality Directorate, University College London Academic Health Sciences Partnership; and director of the Thrombosis Research Institute, all in London.

Lord Kakkar completed his medical education at King's College Hospital Medical School, University of London, and was awarded an MBBS in 1988 and a PhD in 1998 from Imperial College, London. He was made a fellow of the Royal College of Surgeons of England in 1992.

Lord Kakkar's research interests include the prevention and treatment of venous and arterial thromboembolic disease and cancer-associated thrombosis. His awards include Hunterian Professor, Royal College of Surgeons of England, 1996; David Patey Prize, Surgical Research Society of Great Britain and Ireland, 1996; Knoll William Harvey Prize, International Society on Thrombosis and Haemostasis, 1997; James IV Association of Surgeons Travelling Fellow, 2006; and Wellcome Memorial Lecture, Royal Society of Medicine, 2009.

Lord Kakkar was made a life peer in 2010 and sits on the cross benches of the House of Lords.

Vijay V Kakkar

*Thrombosis Research Institute, London, United Kingdom,
and Thrombosis Research Institute, Bangalore, India*

Vijay V Kakkar, OBE, FRCS, FRCSE, (Hon) DSc, is emeritus professor at the University of London and founder-president of the Thrombosis Research Institute, London, and founder-chair of the Thrombosis Research Institute, Bangalore.



Professor Kakkar graduated from Vikram University, Ujjain, India, in 1960, and qualified as fellow of the Royal College of Surgeons of Edinburgh and England in 1964.

Professor Kakkar has held a number of appointments at King's College, University of London, and has been the recipient of many distinctions and awards, including a Hunterian Professorship from the Royal College of Surgeons of England, visiting professor of Harvard University, honourable fellowship of the Association of Surgeons of India, a lifetime achievement award from the Union of Angiology, an honorary doctor of science from Loyola University of Chicago, and in 2010, he was awarded an Order of the British Empire (OBE). He is a member of a number of professional societies and was a founding member of the British Society of Haemostasis and Thrombosis. His publications include more than 680 original articles, 6 books, and contributions to more 50 books.

In 1989, Professor Kakkar established the Thrombosis Research Institute as a national resource to provide a multidisciplinary environment dedicated to the study of thrombosis and related disorders.



Mark Levine

McMaster University, Hamilton, Ontario, Canada

Mark Levine is Chair and Professor in the Department of Oncology at McMaster University, Hamilton, Ontario, Canada. He holds the Buffett Taylor Chair in Breast Cancer Research at McMaster University. He is a past recipient of the O. Harold Warwick Prize (1999) from the National Cancer Institute of Canada. Dr Levine received his medical degree from McGill University, Montreal, Quebec, Canada, and completed his residency in internal medicine at McMaster University. He completed his training in hematology and oncology at Duke University Medical Centre, Durham, North Carolina, USA. In addition, Dr Levine received a master's degree in clinical epidemiology and biostatistics from McMaster University.

In 1982, Dr Levine became a member of both the Faculty of Health Sciences at McMaster University, and a medical oncologist at the Hamilton Regional Cancer Centre (now known as the Juravinski Cancer Centre - Hamilton Health Sciences). He was CEO of the Cancer Centre between 1992 and 1999. Over the past 29 years he has been an active researcher in clinical trials and health services research. His focus is in the areas of breast cancer, thromboembolism in malignancy and functional imaging. A number of the trials he has conducted have impacted on health care in both Canada and internationally. He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982 and now is the Director. OCOG is an academic group that designs, coordinates and analyses multicentre trials in cancer. Dr Levine has over 250 publications in peer-reviewed journals and has brought much research funding to McMaster. He was Chair of Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Dr Levine was an Associate Editor of the *Journal of Clinical Oncology* for seven years and now is a Consultant Editor.



Juan I Arcelus

University of Granada Medical School, Hospital Universitario Virgen de las Nieves, Granada, Spain



Juan I Arcelus, MD, PhD, is professor of surgery at the University of Granada Medical School and an attending staff member in the Department of Surgery at the Hospital Universitario Virgen de las Nieves. He graduated in medicine from the University of Granada Medical School in 1982 and later obtained a PhD, specializing in thrombosis from the same university. After residencies in general and gastrointestinal surgery at the University Hospital of Granada, Professor Arcelus was a research fellow in the Department of Surgery at Northwestern University, Chicago, Illinois, USA, from 1989 to 1992. In addition, he was associate director of the Thrombosis and Hemostasis Group at Evanston Hospital, Evanston, Illinois, from 1990 to 1992.

Professor Arcelus has many research interests, including the epidemiology, prevention, treatment, and follow-up of venous thromboembolism (VTE) in patients undergoing general, laparoscopic, and orthopaedic surgery.

He has had an active role in the INvestigators Against ThromboEmbolism (INATE) educational programme since 2001 and is involved in the Spanish Computerized Registry of Patients with Venous Thromboembolism (RIETE). He is also patron of the Spanish Foundation for the Study of Thromboembolism (FUENTE) and is active in both the International Surgical Thrombosis Forum (ISTF) and the European Task Force for Sharing Expertise in Thrombosis (ETFET). In addition, Professor Arcelus is coordinator of the Working Group on Thrombosis of the Spanish Surgeons Association (AEC), which has prepared guidelines for the prevention of VTE in general surgery. He is also a member of the association's Scientific Committee and Board of Directors.

Professor Arcelus has an extensive publications list, including several book chapters as well as original and review papers in peer-reviewed journals on subjects related to VTE. He has delivered more than 200 lectures

in numerous countries and is a reviewer for several journals. He has been appointed by the American College of Chest Physicians (ACCP) as a panelist for the chapter on prevention of VTE in nonorthopaedic surgery in the ninth edition of the ACCP's *Antithrombotic and Thrombolytic Therapy*.

Jean-Pierre Bassand

University of Franche-Comté, Besançon, France

Jean-Pierre Bassand, MD, FESC, FACC, FRCP, is professor of cardiology at the University of Franche-Comté and is the immediate past chair of the Department of Cardiology at the University Hospital Minjoz in Besançon, France.



Dr Bassand completed his medical education at the Faculty of Medicine, University of Franche-Comté. He was appointed associate professor of cardiology in 1980 and full professor at the University of Franche-Comté and chair of the Department of Cardiology in 1992. He was named a fellow of the European Society of Cardiology and of the American College of Cardiology in 1990 and fellow of the Royal College of Physicians (Glasgow) in 2007. He has served as a member of the Board of the European Society of Cardiology for 10 years, including 2 years as president (2002-2004).

Dr Bassand's clinical research interests are in the fields of diagnosis and treatment of venous thromboembolic disease and coronary artery disease, more specifically acute coronary syndromes. He has authored or co-authored more than 200 manuscripts in peer-reviewed journals, including 3 sets of European Society of Cardiology guidelines on the management of acute coronary syndromes and pulmonary embolisms. He was given the honor of delivering the American College of Cardiology Maseri-Florio Lecture in 2009.



Christoph Bode

University Hospital Freiburg, Freiburg, Germany

Christoph Bode, MD, FESC, FACC, FAHA, was born and raised in Cologne, Germany, where he also went to medical school and completed a postdoctoral fellowship at the Institute of Physiological Chemistry. Following a joint appointment at Massachusetts General Hospital and Harvard Medical School under the mentorship of Edgar Haber, MD, he joined the faculty of the University of Heidelberg, where he eventually became full professor. In 1999, he was appointed chair of medicine at the University of Freiburg.

Professor Bode is an interventional cardiologist with a special interest in antithrombotic therapy in cardiovascular diseases. He has devoted much of his research to basic science and holds several patents in molecular targeting for diagnostic, therapeutic, or imaging purposes. He has published several hundred papers in peer-reviewed journals and has served on many editorial boards, including the *European Heart Journal*, *Circulation*, and *Basic Research in Cardiology*. Professor Bode has been awarded a number of special honours and his advice is widely sought by funding and government agencies. He is currently president of the Society of Thrombosis and Haemostasis (GTH).

Henri Bounameaux

University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland

Henri Bounameaux, MD, is professor of medicine, director of the Division of Angiology and Haemostasis, and chair of the Department of Medicine at the University Hospitals of Geneva. He graduated with an MD in Basle, Switzerland, in 1978, and was later board certified in internal medicine and vascular medicine.



Professor Bounameaux's research interests include all aspects of venous thromboembolism. He has authored more than 330 papers in peer-reviewed journals as well as 100 reviews, didactic papers, and book chapters. He acts as a reviewer for the most important publications in the fields of internal and vascular medicine.

Professor Bounameaux was a member of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH) and is presently chair of the ISTH Council.

He has received several awards, including the Karl Rohr Prize of the Swiss Society of Hematology (1991), the Swiss Angiology Prize (1991), the Theodor Naegeli International Thrombosis Award (1995), and an Investigator Recognition Award (2003) and a Distinguished Career Award (2009) from the ISTH.



Harry R Büller

Academic Medical Center, Amsterdam, The Netherlands

Harry R Büller, MD, is professor of internal medicine, specialising in vascular medicine, at the Academic Medical Center in Amsterdam, Holland.

Professor Büller earned his MD and PhD at the University of Amsterdam. After graduating, he completed his research fellowship in haemostasis and thrombosis in the Departments of Medicine and Clinical Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario, Canada.

Professor Büller has authored and co-authored more than 500 scientific articles concerning topics in his field. He has been co-chair of the Amsterdam Institute for Cardiovascular Research and is chair of the Vascular Medicine Working Group. He is a reviewer for the *New England Journal of Medicine*, *Lancet*, *Archives of Internal Medicine*, and *European Journal of Clinical Investigation*, among others. He is a member of the editorial board of the *Annals of Internal Medicine*.

Professor Büller was chair of the 2004 CHEST conference on antithrombotic therapy for venous thromboembolic disease: the Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy. He is the recipient of the Established Investigator Award presented by the Dutch Heart Foundation, and he received the Dutch Society for Vascular Medicine Award in 2005. Since 2008, he has served as honorary professor of the Royal Netherlands Academy of Arts and Sciences.

Stuart Connolly

McMaster University, Hamilton, Ontario, Canada

Stuart Connolly is a professor of medicine at McMaster University, Ontario, Canada, and a cardiac electrophysiologist at Hamilton Health Sciences, Ontario, Canada. Dr Connolly holds a masters degree from Fordham University, New York, USA, and an MD from McGill University, Montreal, Canada. He received his specialist training in cardiology at the University of Toronto, Ontario, Canada, and at Stanford University, California, USA. Dr Connolly became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. As well as being an active clinical cardiologist, Dr Connolly has been the director of the Division of Cardiology since 2005. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.



Dr Connolly has published more than 200 scientific articles in the field and is currently a member of the editorial boards of a number of prominent cardiology journals, including *Heart*, the *American Heart Journal*, and the *Journal of Pacing and Electrophysiology*. Dr Connolly's main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.



John Eikelboom

McMaster University, Hamilton, Ontario, Canada

John Eikelboom, MBBS, MSc, FRCPC, is associate professor, Department of Medicine, McMaster University, and hematologist, Thrombosis Service, Hamilton General Hospital. He completed training in internal medicine and hematology in Perth, Australia, in 1998, and subsequently undertook a fellowship in thrombosis medicine and clinical epidemiology at McMaster University. In 2005, he assumed a Tier II Canada Research Chair in cardiovascular medicine from the Canadian Institutes of Health Research.

Dr Eikelboom is a member of the editorial boards of *Thrombosis and Hemostasis* and the *Canadian Journal of Cardiology*, and serves on the advisory board for the *Journal of Thrombosis and Haemostasis*. He has been involved in and led multiple mechanistic and clinical outcome studies of antithrombotic therapies in cardiovascular medicine. His current research, supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies, the prognostic importance of bleeding and transfusion, and the mechanisms of variable response to antiplatelet drugs.

Dr Eikelboom has authored more than 230 articles in peer-reviewed journals.

Keith A A Fox

University of Edinburgh, Edinburgh, United Kingdom

Keith A A Fox, MBChB, FRCP, FESC, FMedSci, is British Heart Foundation and Duke of Edinburgh Professor of Cardiology of the University of Edinburgh, and head of Medical and Radiological Sciences and consultant cardiologist at the Royal Infirmary of Edinburgh.




Professor Fox was a founding fellow of and is on the board of the European Society of Cardiology (ESC). He is chair-elect of the Scientific Programme Committee of the ESC (chair 2012-14). In addition, he is president of the British Cardiovascular Society (2009 to 2012). Professor Fox gave the State-of-the-Art Lecture on Acute Coronary Syndromes at the American Heart Association as well as the 2009 Plenary Lecture at the European Society of Cardiology – American College of Cardiology Symposium, and has delivered a series of named lectures at national and international symposia.

Professor Fox's major research interest lies in the mechanisms and manifestations of acute coronary arterial disease. His work extends from underlying biological mechanisms to in vitro and in vivo studies and clinical trials. He is the author of more than 520 scientific papers.

Professor Fox is chair of the RITA programme, co-chair of ROCKET-AF, chair of the GRACE programme (the largest multinational study in acute coronary syndromes), and a lead investigator for studies on novel antithrombins.

He is an international associate editor of the *European Heart Journal* and a member of the editorial boards of a number of other journals. His current areas of research include the inhibition of coronary thrombosis and the role of platelets and inflammation in acute coronary syndromes.



Christopher B Granger

*Duke University Medical Center, Durham,
North Carolina, USA*

Christopher B Granger MD, FACC, is a professor of medicine in the Division of Cardiology at Duke University and director of the Cardiac Care Unit for the Duke University Medical Center. Dr Granger is a fellow of the American College of Cardiology, the American Heart Association, and the European Society of Cardiology. He is associate editor of the *American Heart Journal* and serves on the editorial board of the *Journal of the American College of Cardiology*. He is a cardiology section author for *Current Medical Diagnosis and Treatment*. Dr Granger serves on the publication oversight committee of the American Heart Association and is chair of the Advisory Working Group of the American Heart Association Mission: Lifeline program. He is a member of the 2011 ACC/AHA STEMI Guidelines Committee, has served on FDA advisory committees on an ad hoc basis, and is on the Board of External Experts of the National Heart, Lung and Blood Institute.

Dr Granger's primary research interest is in the delivery and methodology of large, randomized, clinical trials in heart disease. He has co-authored more than 400 peer-reviewed manuscripts and currently serves on a number of clinical trial steering committees and data safety monitoring committees. Dr Granger has coordinated the Duke Clinical Research Institute's activities in many clinical trials evaluating acute myocardial infarction (MI) reperfusion and antithrombotic strategies in acute coronary syndromes and in atrial fibrillation.

Dr Granger is co-chair of the steering committee of the ARISTOTLE trial assessing an oral factor Xa inhibitor for stroke prevention in atrial fibrillation. In addition, he is co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) projects – state-wide programs to improve reperfusion care for acute MI and care for cardiac arrest.

Ian A Greer

University of Liverpool, Liverpool, United Kingdom

Ian A Greer, MBChB/MD, FRCP(Glas), FRCPE, FRCPI, FAE, FFSRH, FCCP, FRCOG, FMedSci, is executive pro-vice-chancellor of the Faculty of Health and Life Sciences at the University of Liverpool and professor of obstetric medicine and honorary consultant obstetrician at Liverpool Women's Hospital NHS Foundation Trust. Previous posts include: dean and professor of obstetric medicine at Hull York Medical School; honorary consultant obstetrician at Hull and East Yorkshire NHS Trust; Regius Professor of obstetrics and gynaecology and deputy dean of the Medical Faculty at the University of Glasgow; clinical scientist at the Medical Research Council (MRC) Reproductive Biology Unit, Edinburgh; and consultant obstetrician at the Royal Infirmary, Edinburgh.



Professor Greer graduated from the University of Glasgow with postgraduate training in internal medicine/haemostasis and thrombosis as well as obstetrics and gynaecology. He has been awarded the MRCOG Gold Medal, the William Blair Bell Memorial Lectureship of the Royal College of Obstetricians and Gynaecologists, the Bernhard Baron Travelling Scholarship in Obstetrics and Gynaecology of the Royal College of Obstetricians and Gynaecologists, and the Watson Prize Lectureship of the Royal College of Physicians and Surgeons of Glasgow.

He is currently chair of the Medical Research Council's (MRC) Translational Stem Cell Research Committee. He previously served on the MRC's Physiological Systems and Clinical Sciences Board (deputy chair, 2006-2008) and its Strategic Portfolio Overview Group; the Pilot Industry Collaboration Awards Scheme Panel (chair); the Clinical Trials Cross-Board Group; the Interventions Evaluation Platforms Panel; and the Biomarkers Awards Panel. Professor Greer was co-chair of the Scientific and Standardisation Subcommittee on Women's Health of the International Society on Thrombosis and Haemostasis (2003-2007) and co-chair of the first through fourth Women's Health Issues in Haemostasis and Thrombosis conferences.

He has been a member of the American College of Chest Physicians' sixth through ninth Consensus Panels on Antithrombotic Therapy and was chair of the UK's National Advisory Committee for Enquiries into Maternal and Child Health (2005-2011).

Professor Greer's clinical practice and research focuses on high-risk pregnancy, medical disorders in pregnancy, and women's vascular health, particularly in relation to haemostasis and thrombosis. He has authored, co-authored, or edited 12 textbooks or speciality books for health care professionals (including textbooks on maternal medicine, obstetric haematology, pre-term labour, and women's vascular health). He has also authored 2 undergraduate textbooks and one postgraduate textbook in obstetrics/gynaecology), as well as 2 books for a wider, public audience (*Pregnancy: The Inside Guide* [Collins, 2003] and *Fertility and Conception*, [Collins, 2007]). He has led or contributed to the development of 21 national or international guidelines and has published more than 380 peer-reviewed original papers, review articles, and book chapters relating largely to medical disorders in pregnancy, haemostasis and thrombosis, and vascular disease in women.

Craig M Kessler

Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center, Washington, DC, USA

Craig M Kessler, MD, received his medical degree from the Tulane University School of Medicine in New Orleans, Louisiana, where he was a member of Alpha Omega Alpha Honor Society. He completed his residency in internal medicine at the Ochsner Foundation Hospital in Louisiana and his fellowship in hematology/oncology at the Johns Hopkins Hospital and University in Baltimore, Maryland.



Dr Kessler then became a full-time faculty member and attending physician in the Section of Special Hematology at the National Institutes of Health in Bethesda, Maryland. In 1982, he joined the Division of Hematology and Oncology at the George Washington University School of Medicine, where he became tenured professor of medicine and chief of the division. He is currently professor of medicine and pathology at the Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center. In addition, Dr Kessler is director of the Division of Coagulation, director of cellular and therapeutic apheresis, director of the Hemophilia and Thrombophilia Comprehensive Treatment Center, and immediate past chief of the Division of Hematology/Oncology.

He is co-editor of *Haemophilia* and *Seminars in Thrombosis and Hemostasis*, and is chair of the Medical and Scientific Advisory Council of the National Hemophilia Foundation. Dr Kessler has been awarded Mastership in the American College of Physicians and has published 4 books and more than 175 peer-reviewed articles.



Gilles Montalescot

Pitié-Salpêtrière University Hospital, Institute of Cardiology, University of Paris VI, Paris, France

Gilles Montalescot, MD, PhD, is professor of cardiology at Pitié-Salpêtrière Hospital and heads the Cardiac Care Unit. He is a practicing interventional cardiologist and has extensive experience in basic and clinical research. He is the director of the INSERM Research Unit U937 on Thrombosis.

Professor Montalescot has been an investigator for many of the new drugs developed in the past 15 years, as well as for many of the new interventional technologies. He is a senior scientist and has been the lead investigator of many national and international randomised trials, including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, and the ongoing AMERICA, ARCTIC, ACCOAST, ATLANTIC, and ALBATROSS trials. Professor Montalescot is chair of the ACTION Study Group, an academic research organization based at Pitié-Salpêtrière Hospital.

Professor Montalescot has served on several task force committees on antithrombotic drugs and acute coronary syndromes, and he is the current chair of the Stable Coronary Artery Disease Guidelines of the European Society of Cardiology. Professor Montalescot has received several awards in France, including the J. Valade Prize from the Fondation de France and the J. Escalle Award from the National Academy of Medicine. He is a member of several editorial boards and has published more than 350 peer-reviewed original articles in journals such as *The New England Journal of Medicine*, *JAMA*, *Lancet*, and *Circulation*. He has also lectured at numerous international events.

Paolo Prandoni

*Institute of Medical Semeiotics, University of Padua,
Padua, Italy*



Paolo Prandoni, PhD, is professor of the Department of Medical and Surgical Sciences, Thromboembolism Unit, at the University of Padua. He trained at the University of Padua from 1971 to 1979 before moving to The Netherlands where he studied for his PhD at the University of Amsterdam in 1992.

Professor Prandoni's research and professional experiences encompass the epidemiology, diagnosis, and management of thromboembolism. Of particular interest to him are studies addressing cancer-associated venous thromboembolism (VTE).

His key achievements include the following: demonstration of the value of real-time compression ultrasonography for the diagnosis of deep vein thrombosis (DVT); confirmation of the risk for subsequent overt cancer in patients with idiopathic VTE; demonstration that low-molecular-weight heparins (LMWHs) are as effective and safe as unfractionated heparin in the treatment of DVT; demonstration that LMWHs allow the home treatment of DVT; description of the natural history of DVT, outlining the particularly high risk of recurrent thromboembolism in cancer patients; demonstration that both factor V Leiden and G20210A prothrombin variant are independent risk factors for recurrent VTE; demonstration that residual vein thrombosis is a predictive marker of recurrent thromboembolism; demonstration that cancer patients with venous thrombosis have a high risk of recurrent thromboembolism while on anticoagulation; demonstration of an association between atherosclerosis and venous thrombosis; and demonstration that chronic pulmonary thromboembolic hypertension following an episode of pulmonary embolism is more frequent than commonly thought.

Professor Prandoni has published more than 300 papers in peer-reviewed journals.



Alexander G G Turpie

*McMaster University and Hamilton Health Sciences,
Hamilton, Ontario, Canada*

Alexander G G Turpie, MD, is professor of medicine at McMaster University and an internist on the staff of Hamilton Health Sciences. He received his medical education from the University of Glasgow, Scotland. After completing residencies at the Glasgow Royal Infirmary and Stobhill General Hospital, where he was also a clinical research fellow, he served as a clinic lecturer for the University of East Africa Medical School in Nairobi, Kenya. After returning to the University of Glasgow for additional training in haemostasis and thrombosis, he was appointed MRC Fellow at McMaster University as well as being appointed to the full-time faculty in the Department of Medicine.

Professor Turpie's research interests include new antithrombotic drugs for the management of venous and arterial thrombosis, and anticoagulant therapy in patients with prosthetic heart valves. He has served on numerous professional and university-related committees and is a frequent lecturer at professional meetings worldwide.

Professor Turpie has authored more than 700 published articles, abstracts, book chapters, and books, and he has been a reviewer for many journals, including the *Annals of Internal Medicine*, *Circulation*, *The Lancet*, and the *New England Journal of Medicine*, in addition to serving on the editorial boards of *Vascular Medicine* and *Heart Drug*.

Freek W A Verheugt

University Hospital, Nijmegen, and Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

Freek W A Verheugt, MD, FESC, FACC, FAHA, is professor of cardiology at the Heart-Lung Centre of the University Medical Centre of Nijmegen and chair of the Department of Cardiology at Onze Lieve Vrouwe Gasthuis.



Professor Verheugt graduated from the University of Amsterdam in 1974 and wrote a thesis on platelet and granulocyte antigens and antibodies. He trained in cardiology at the Thoraxcenter of the Erasmus University in Rotterdam. Professor Verheugt has served as professor at the University of Colorado Health Sciences Center in Denver, Colorado, USA, and at the Free University in Amsterdam. He was president of the Netherlands Society of Cardiology from 1999 to 2001.

Professor Verheugt has published more 400 papers in peer-reviewed international journals, including the *New England Journal of Medicine*, *The Lancet*, *Circulation*, *Journal of the American College of Cardiology*, and *European Heart Journal*, of which he is an editorial board member. He is an editorial adviser of *The Lancet*, the *New England Journal of Medicine*, and *Circulation*. Professor Verheugt has more than 14,000 citations. His main fields of scientific interest are pharmacological and interventional treatments of acute coronary syndromes and atrial fibrillation.





Organised under the auspices of the Thrombosis Research Institute, London, United Kingdom and supported by an unrestricted educational grant from Bristol-Myers Squibb, Pfizer and Bayer Healthcare Pharmaceuticals.